Pharming

Pharming develops and delivers treatments for rare immunological and genetic diseases.

The page describes Pharming’s clinical trials in rare diseases and how to participate.

The page details Pharming’s clinical-stage pipeline, including therapies like leniolisib and napazimone.

The page covers Pharming’s approved therapies, RUCONEST and Joenja (leniolisib), including regulatory details.

Pharming hosted a presentation at #AAAAI2024 on diagnosing and managing infections, lymphadenopathy, and atopy, featuring physicians experienced in activated PI3K delta syndrome (APDS).

Tyler was one of the first people in the world to be diagnosed with APDS (activated PI3K delta syndrome). This is his journey.

The page shares stories from patients and families living with rare diseases.

The page provides updates on Pharming Group’s news, press releases, and company milestones.

Pharming announced acceptance of a late-breaking abstract on leniolisib’s Phase II trial results for PI3Kd-linked immunodeficiencies at the 22nd European Society for Immunodeficiencies meeting.

Leiden, the Netherlands, May 7, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced presentations at the 2026 Annual Meeting of the Clinical Immunology Society (CIS), taking place May 6-9 in New Orleans, LA.

Pharming Group (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced that shareholders approved all proposals presented at its Annual General Meeting of Shareholders (AGM), held earlier today.

Pharming offers career opportunities in advancing rare disease therapies.

The page describes the workplace culture at Pharming, driven by science and purpose in rare disease care.

Pharming’s Board of Directors provides industry, clinical, and real-world expertise to guide the company’s global rare disease initiatives.

The page outlines Pharming’s corporate governance framework, board of directors, and compliance policies.

A leadership team defined by an unwavering commitment to challenging what’s possible for individuals and families affected by rare diseases.

The page describes Pharming’s three-decade legacy in advancing rare disease care, including key milestones and mission.

Finding collaborative solutions for some of the toughest rare disease challenges.

Pharming collaborates with the rare disease community to drive progress for patients and caregivers.

Pharming is a global biotechnology company focused on supporting people with rare diseases.

The page provides contact details for Pharming Group, including side effect reporting, office locations, and news subscriptions.

The page explains how to report side effects from Pharming products, with contact information for multiple regions.

Victoria, living with hereditary angioedema